Based on this, the combination of PARP inhibitors and inhibiting androgens by NHTs is considered to be a potential treatment strategy for the broader PC population, prompting extensive preclinical and clinical exploration by researchers. The gene discussed is PARP1; the disease is pachyonychia congenita.